Marken, the clinical trial logistics operation with UPS Healthcare, has expanded its global network to support increased demand for its clinical drug supply chain services, particularly for cell and gene clinical trials. Plans for the remainder of 2021 and 2022 will support accelerated demand for mRNA therapies, cell and gene therapies, early access and managed access programs. Expansion plans include new locations, expanded cold chain services and packaging solutions.
Marken's ongoing and planned investments include:
This new control center, combined with the existing control center in Durham, NC, US, will support 24/7/365 global monitoring of all complex shipments, including cell and gene shipments.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.